BriaCell Therapeutics ((TSE:BCT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics is conducting a Phase I/II clinical study titled ‘A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab’. The study aims to evaluate the safety and efficacy of the SV-BR-1-GM regimen combined with retifanlimab in patients with metastatic or locally recurrent breast cancer who have not responded to standard treatments. This research is significant as it explores potential new treatment options for challenging cancer cases.
The study tests an experimental combination of biological and drug interventions, including SV-BR-1-GM, low dose cyclophosphamide, interferon inoculation, and retifanlimab. These interventions are designed to enhance the immune response against cancer cells.
The study employs a randomized, single-group assignment with no masking, focusing primarily on treatment. Patients are divided into two experimental arms to assess different sequences of administering the combination therapy.
The study began on October 23, 2017, and is currently enrolling by invitation. The last update was submitted on February 3, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
The update on this study could influence BriaCell Therapeutics’ stock performance positively, as successful outcomes may enhance investor confidence and market positioning. It also positions the company competitively within the oncology sector, where innovative treatments are highly valued.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.